Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma

British Journal of Cancer

Volumn 112, Issue 1, 2015, Pages 112-121

  Yang, H ^a   Lan, P ^a   Hou, Z ^a   Guan, Y ^a   Zhang, J ^a   Xu, W ^a   Tian, Z ^b   Zhang, C ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

hepatocellular carcinoma (HCC); histone deacetylase inhibitor (HDACi); MCM7; MICA; microRNA; natural killer cells

Indexed keywords

MHC CLASS I RELATED CHAIN MOLECULE A PROTEIN; MHC CLASS I RELATED CHAIN MOLECULE B PROTEIN; MICRORNA; MICRORNA 106B; MICRORNA 17 92; MICRORNA 20A; MICRORNA 93; MINICHROMOSOME MAINTENANCE PROTEIN 7; PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; HLA ANTIGEN CLASS 1; HYDROXAMIC ACID; MCM7 PROTEIN, HUMAN; MHC CLASS I-RELATED CHAIN A; MIRN17-92 MICRORNA, HUMAN;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NATURAL KILLER CELL; PHARMACOGENETICS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; TRANSCRIPTION REGULATION; TUMOR CELL DESTRUCTION; UPREGULATION; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; GENETIC TRANSFECTION; GENETICS; HEPG2 CELL LINE; LIVER NEOPLASMS; METABOLISM; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; EPIGENOMICS; HEP G2 CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LIVER NEOPLASMS; MICRORNAS; MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 7; TRANSFECTION; UP-REGULATION;

EID: 84920690806     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.547     Document Type: Article

References (50)

1. Alao JP, Stavropoulou AV, Lam EW, Coombes RC, Vigushin DM (2006) Histone deacetylase inhibitor, trichostatin A induces ubiquitin-dependent cyclin D1 degradation in MCF-7 breast cancer cells. Mol Cancer 5: 8.
2. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR (2005) Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 65(14): 6321-6329.
3. Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK, Johnstone RW (2013) HDAC inhibitors induce tumor-cellselective pro-apoptotic transcriptional responses. Cell Death Dis 4: e519.
4. Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, Ulrich S, Speich R, Huber LC (2009) Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res 104(10): 1184-1191.
5. Chen WY, Weng JH, Huang CC, Chung BC (2007) Histone deacetylase inhibitors reduce steroidogenesis through SCF-mediated ubiquitination and degradation of steroidogenic factor 1 (NR5A1). Mol Cell Biol 27(20): 7284-7290.
6. Chou CW, Wu MS, Huang WC, Chen CC (2011) HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One 6(3): e18087.
7. Dawson MA, Kouzarides T (2012) Cancer epigenetics: from mechanism to therapy. Cell 150(1): 12-27.
8. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC (2005) Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 45: 495-528.
9. Duan H, Heckman CA, Boxer LM (2005) Histone deacetylase inhibitors down-regulate bcl-2 expression and induce apoptosis in t(14;18) lymphomas. Mol Cell Biol 25(5): 1608-1619.
10. Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR (2007) Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 109(1): 31-39.
11. Ferguson M, Henry PA, Currie RA (2003) Histone deacetylase inhibition is associated with transcriptional repression of the Hmga2 gene. Nucleic Acids Res 31(12): 3123-3133.
12. Fiegler N, Textor S, Arnold A, Rolle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A (2013) Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 122(5): 684-693.
13. Grillari J, Hackl M, Grillari-Voglauer R (2010) miR-17-92 cluster: ups and downs in cancer and aging. Biogerontology 11(4): 501-506.
14. Gupta M, Han JJ, Stenson M, Wellik L, Witzig TE (2012) Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 26(6): 1356-1364.
15. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ, Hammond SM (2005) A microRNA polycistron as a potential human oncogene. Nature 435(7043): 828-833.
16. Hou ZH, Han QJ, Zhang C, Tian ZG, Zhang J (2014) miR146a impairs the IFN-induced anti-HBV immune response by downregulating STAT1 in hepatocytes. Liver Int 34(1): 58-68.
17. Ji M, Rao E, Ramachandrareddy H, Shen Y, Jiang C, Chen J, Hu Y, Rizzino A, Chan WC, Fu K, McKeithan TW (2011) The miR-17-92 microRNA cluster is regulated by multiple mechanisms in B-cell malignancies. Am J Pathol 179(4): 1645-1656.
18. Khan SN, Khan AU (2010) Role of histone acetylation in cell physiology and diseases: an update. Clin Chim Acta 411(19-20): 1401-1411.
19. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW (2001) Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7(4): 437-443.
20. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN (2004) MicroRNA genes are transcribed by RNA polymerase II. EMBO J 23(20): 4051-4060.
21. Li BQ, Yu H, Wang Z, Ding GH, Liu L (2013)MicroRNA mediated network and DNA methylation in colorectal cancer. Protein Pept Lett 20(3): 352-363.
22. Luesink M, Hollink IH, van der Velden VH, Knops RH, Boezeman JB, de Haas V, Trka J, Baruchel A, Reinhardt D, van der Reijden BA, van den Heuvel-Eibrink MM, Zwaan CM, Jansen JH (2012) High GATA2 expression is a poor prognostic marker in pediatric acute myeloid leukemia. Blood 120(10): 2064-2075.
23. Mateen S, Raina K, Jain AK, Agarwal C, Chan D, Agarwal R (2012) Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells. Epigenetics 7(10): 1161-1172.
24. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci USA 101(2): 540-545.
25. Nagel S, Venturini L, Przybylski GK, Grabarczyk P, Schmidt CA, Meyer C, Drexler HG, Macleod RA, Scherr M (2009) Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk Lymphoma 50(1): 101-108.
26. Nimmanapalli R, Fuino L, Bali P, Gasparetto M, Glozak M, Tao J, Moscinski L, Smith C, Wu J, Jove R, Atadja P, Bhalla K (2003) Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylatesensitive or -refractory chronic myelogenous leukemia-blast crisis cells. Cancer Res 63(16): 5126-5135.
27. Noh EJ, Lee JS (2003) Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2-M transition. Biochem Biophys Res Commun 310(2): 267-273.
28. O'Connell RM, Rao DS, Baltimore D (2012) microRNA regulation of inflammatory responses. Annu Rev Immunol 30: 295-312.
29. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435(7043): 839-843.
30. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y, Seto M (2004) Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 64(9): 3087-3095.
31. Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia S, Alder H, Ruco LP, Baldassarre G, Croce CM, Vecchione A (2008) E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 13(3): 272-286.
32. Poliseno L, Salmena L, Riccardi L, Fornari A, Song MS, Hobbs RM, Sportoletti P, Varmeh S, Egia A, Fedele G, Rameh L, Loda M, Pandolfi PP (2010) Identification of the miR-106b~25 microRNA cluster as a protooncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal 3(117): ra29.
33. Qu J, Hou Z, Han Q, Jiang W, Zhang C, Tian Z, Zhang J (2014) Intracellular poly(I:C) initiated gastric adenocarcinoma cell apoptosis and subsequently ameliorated NK cell functions. J Interferon Cytokine Res 34(1): 52-59.
34. Richon VM, Sandhoff TW, Rifkind RA, Marks PA (2000) Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA 97(18): 10014-10019.
35. Sato Y (2013) Is histone deacetylase-9-MicroRNA-17~92 cluster a novel axis for angiogenesis regulation? Arterioscler Thromb Vasc Biol 33(3): 445-446.
36. Scian MJ, Carchman EH, Mohanraj L, Stagliano KE, Anderson MA, Deb D, Crane BM, Kiyono T, Windle B, Deb SP, Deb S (2008) Wild-type p53 and p73 negatively regulate expression of proliferation related genes. Oncogene 27(18): 2583-2593.
37. Setiadi AF, Omilusik K, David MD, Seipp RP, Hartikainen J, Gopaul R, Choi KB, Jefferies WA (2008) Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res 68(23): 9601-9607.
38. Stern-Ginossar N, Gur C, Biton M, Horwitz E, Elboim M, Stanietsky N, Mandelboim M, Mandelboim O (2008) Human microRNAs regulate stress-induced immune responses mediated by the receptor NKG2D. Nat Immunol 9(9): 1065-1073.
39. Struhl K (1998) Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 12(5): 599-606.
40. Su C, Hou Z, Zhang C, Tian Z, Zhang J (2011) Ectopic expression of microRNA-155 enhances innate antiviral immunity against HBV infection in human hepatoma cells. Virol J 8: 354.
41. Sun X, Zhang J, Wang L, Tian Z (2008) Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett 262(2): 201-213.
42. Takada S, Asahara H (2012) Current strategies for microRNA research. Mod Rheumatol 22(5): 645-653.
43. Ting CN, Olson MC, Barton KP, Leiden JM (1996) Transcription factor GATA-3 is required for development of the T-cell lineage. Nature 384(6608): 474-478.
44. Woods K, Thomson JM, Hammond SM (2007) Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 282(4): 2130-2134.
45. Yan HL, Xue G, Mei Q, Wang YZ, Ding FX, Liu MF, Lu MH, Tang Y, Yu HY, Sun SH (2009) Repression of the miR-17-92 cluster by p53 has an important function in hypoxia-induced apoptosis. EMBO J 28(18): 2719-2732.
46. Yang H, Xu W, Li Y, Lan P, Zhang J, Zhang Y, Zhang C (2014) Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by induction p21WAF1 expression and cell cycle arrest. Anticancer Drugs 25(7): 767-777.
47. You JS, Kang JK, Lee EK, Lee JC, Lee SH, Jeon YJ, Koh DH, Ahn SH, Seo DW, Lee HY, Cho EJ, Han JW (2008) Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene 27(10): 1376-1386.
48. Zhang C, Wang Y, Zhou Z, Zhang J, Tian Z (2009) Sodium butyrate upregulates expression of NKG2D ligand MICA/B in HeLa and HepG2 cell lines and increases their susceptibility to NK lysis. Cancer Immunol Immunother 58(8): 1275-1285.
49. Zhang Y, Lin A, Zhang C, Tian Z, Zhang J (2014) Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9. Cancer Immunol Immunother 63(4): 357-367.
50. Zhao ZN, Bai JX, Zhou Q, Yan B, Qin WW, Jia LT, Meng YL, Jin BQ, Yao LB, Wang T, Yang AG (2012) TSA suppresses miR-106b-93-25 cluster expression through downregulation of MYC and inhibits proliferation and induces apoptosis in human EMC. PLoS One 7(9): e45133.